Catalent beats revenue estimates ahead of deal close with Novo Holdings, ET HealthWorld
Bengaluru: Contract drug manufacturer Catalent beat analysts’ estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies. WHY IT’S IMPORTANT The…